Jul 25, 2022 · Kyowa Kirin has discontinued the clinical development of its investigational treatment, KW-6356, for Parkinson’s disease, despite Phase 2 clinical trial data showing promising results as a monotherapy or in combination with levodopa.

KW-6356 is a novel adenosine A 2A (A 2A) receptor antagonist/inverse agonist, and its efficacy as monotherapy in Parkinson's disease (PD) patients has been reported.

Mar 23, 2025 · Sipagladenant (KW-6356) is a non-xanthine selective antagonist/inverse agonist of the adenosine A 2A receptor that was previously under development by Kyowa Kirin as a monotherapy and adjunctive to levodopa therapy in Parkinsonism.

May 1, 2023 · Kyowa Kirin’s KW-6356, or sipagladenant , is a non-xanthine A 2A receptor intended to treat Parkinson’s disease. Unlike Kyowa Kirin’s recently US-approved neutral antagonist, istradefylline, the molecule is an [...]

Dec 1, 2023 · We evaluated the efficacy and safety of KW-6356 as monotherapy in patients with early, untreated Parkinson's disease (PD).

Sep 18, 2022 · In a phase 2b randomized, placebo-controlled study (NCT03703570), KW-6356, a selective antagonist of adenosine A2A receptors developed by Kyowa Hakko Kirin, demonstrated a favorable efficacy and safety profile as an adjunct treatment to levodopa in patients with Parkinson disease (PD).

Kyowa Kirin conducted Phase 2 clinical studies of KW-6356 in Japan for Parkinson's disease and found it to be potentially effective in relieving motor and non-motor symptoms both as monotherapy and in combination with levodopa-containing therapy.

Oct 21, 2020 · KW-6356 has a high affinity and selectivity for adenosine A 2A receptors, and is therefore expected to obtain approval for wider indications as the next generation of Istradefylline, which was launched in the United States (brand name: NOURIANZ®) and Japan (brand name: NOURIAST®) by Kyowa Kirin.

Oct 21, 2020 · KW-6356 has a high affinity and selectivity for adenosine A2A receptors, and is therefore expected to obtain approval for wider indications as the next generation of Istradefylline, which was launched in the United States (brand name: NOURIANZ®) and Japan (brand name: NOURIAST®) by Kyowa Kirin.

Jul 15, 2022 · KW-6356 is a follow-up to Kyowa Kirin's first-generation adenosine A2 antagonist Nourianz/Nouriast (istradefylline), which finally claimed FDA approval in 2019 as an...